Effect of sodium valproate tablets and venlafaxine hydrochloride sustained-release tablets in the treatment of female schizophrenia with affective disorder

Abstract

Objective To investigate the clinical effect of sodium valproate tablets combined with venlafaxine hydrochloride sustained-release tablets in female patients with schizophrenia complicated with affective disorders and its influence on the recurrence time. Methods From January 2013 to July 2016, 98 female patients with schizophrenia complicated by affective disorder in Taiyuan Mental Hospital were selected and randomly divided into single group (n=49) and combination group (n=49) according to the digital table.The single drug group was treated with sodium valproate tablets, and the combination group was treated with venlafaxine hydrochloride sustained-release tablets on the basis of a single drug group.The clinical efficacy and recurrence time of the two groups were compared. Results The scores of withdrawal symptoms[(4.39±0.94)points], positive symptoms[(11.55±4.30)points], negative symptoms[(11.09±1.21)points] and psychiatric symptoms[(12.01±2.16)points] in the combination group were all significantly lower than those at 1 month after treatment[(10.98±1.43)points, (16.74±3.89)points, (18.43±2.05)points, (19.83±3.44)points](t=12.957, 18.471, all P<0.05). The incubation period and amplitude of the P300 potentials in the combination group were (314.55±9.21)s, (4.05±1.76)s, respectively, which were both higher than those of the single drug group[(341.60±25.87)s, (2.58±2.30)s](t=18.251, 15.738, all P<0.05). The eye movements of the combination group 12 weeks after operaion were (27.30±1.41)s and (6.15±0.98)s, respectively, which were higher than those of the single drug group[(25.10±2.93)s and (5.10±1.20)s](t=13.992 , 15.836, all P<0.05). The recurrence rate of the combined group was 8.16%, which was lower than 18.37% of the single drug group(χ2=6.893, P<0.05). The hospitalization duration[(14.83±4.61)d], symptom improvement time[(34.94±7.85)d] of the combined group were shorter than those of the single drug group [(27.91±7.49)d, (59.81±10.94)d](t=18.946, 21.461, all P<0.05). The recurrence time at 12 weeks after treatment of the combination group was (148.48±33.19)d, which was longer than (109.46±28.88)d of the single drug group(t=16.893, P<0.05). Conclusion The combination of sodium valproate tablets and venlafaxine hydrochloride sustained-release tablets in patients with schizophrenia complicated with affective disorders can improve the clinical effect, shorten the recurrence time and improve the cognitive function of patients, which is worth popularizing and applying. Key words: Schizophrenia; Affective disorders, psychotic; Valproate tablets; Venlafaxine hydrochloride sustained release tablets; Recurrence; Cognition; Female